Boston Scientific Corporation (NYSE:BSX) Shares Sold by Dupont Capital Management Corp

Dupont Capital Management Corp reduced its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 19.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,944 shares of the medical equipment provider's stock after selling 28,493 shares during the period. Boston Scientific comprises 1.3% of Dupont Capital Management Corp's investment portfolio, making the stock its 26th biggest position. Dupont Capital Management Corp's holdings in Boston Scientific were worth $11,596,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Brighton Jones LLC increased its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in Boston Scientific in the fourth quarter valued at $33,074,000. Bank Pictet & Cie Europe AG increased its stake in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. J.W. Cole Advisors Inc. lifted its position in Boston Scientific by 24.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 4,999 shares of the medical equipment provider's stock worth $447,000 after buying an additional 985 shares during the period. Finally, Highview Capital Management LLC DE boosted its stake in Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after buying an additional 1,439 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer now directly owns 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 411,970 shares of company stock valued at $42,406,693 over the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Down 0.0%

BSX traded down $0.02 on Friday, reaching $101.35. The company's stock had a trading volume of 11,349,521 shares, compared to its average volume of 6,583,316. Boston Scientific Corporation has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The stock has a market cap of $149.95 billion, a price-to-earnings ratio of 73.98, a price-to-earnings-growth ratio of 2.62 and a beta of 0.68. The business's 50 day moving average is $101.77 and its 200 day moving average is $99.11.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company's revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.56 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BSX. Leerink Partners initiated coverage on shares of Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Royal Bank Of Canada boosted their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. BTIG Research restated a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Finally, Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $116.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.